AIM: To investigate whether strontium ranelate (SR), a new antiosteoporotic agent, could attenuate cartilage degeneration and subchondral bone remodeling in osteoarthritis (OA). METHODS: Medial meniscal tear (MMT) operation was performed in adult SD rats to induce OA. SR (625 or 1800 mg·kg(-1)·d(-1)) was administered via gavage for 3 or 6 weeks. After the animals were sacrificed, articular cartilage degeneration was evaluated using toluidine blue O staining, SOX9 immunohistochemistry and TUNEL assay. The changes in microarchitecture indices and tissue mineral density (TMD), chemical composition (mineral-to-collagen ratio), and intrinsic mechanical properties of the subchondral bones were measured using micro-CT scanning, confocal Raman microspectroscopy and nanoindentation testing, respectively. RESULTS: The high-dose SR significantly attenuated cartilage matrix and chondrocyte loss at 6 weeks, and decreased chondrocyte apoptosis, improved the expression of SOX9, a critical transcription factor responsible for the expression of anabolic genes type II collagen and aggrecan, at both 3 and 6 weeks. Meanwhile, the high-dose SR also significantly attenuated the subchondral bone remodeling at both 3 and 6 weeks, as shown by the improved microarchitecture indices, TMD, mineral-to-collagen ratio and intrinsic mechanical properties. In contrast, the low-dose SR did not significantly change all the detection indices of cartilage and bone at both 3 and 6 weeks. CONCLUSION: The high-dose SR treatment can reduce articular cartilage degeneration and subchondral bone remodeling in the rat MMT model of OA.
AIM: To investigate whether strontium ranelate (SR), a new antiosteoporotic agent, could attenuate cartilage degeneration and subchondral bone remodeling in osteoarthritis (OA). METHODS: Medial meniscal tear (MMT) operation was performed in adult SD rats to induce OA. SR (625 or 1800 mg·kg(-1)·d(-1)) was administered via gavage for 3 or 6 weeks. After the animals were sacrificed, articular cartilage degeneration was evaluated using toluidine blue O staining, SOX9 immunohistochemistry and TUNEL assay. The changes in microarchitecture indices and tissue mineral density (TMD), chemical composition (mineral-to-collagen ratio), and intrinsic mechanical properties of the subchondral bones were measured using micro-CT scanning, confocal Raman microspectroscopy and nanoindentation testing, respectively. RESULTS: The high-dose SR significantly attenuated cartilage matrix and chondrocyte loss at 6 weeks, and decreased chondrocyte apoptosis, improved the expression of SOX9, a critical transcription factor responsible for the expression of anabolic genes type II collagen and aggrecan, at both 3 and 6 weeks. Meanwhile, the high-dose SR also significantly attenuated the subchondral bone remodeling at both 3 and 6 weeks, as shown by the improved microarchitecture indices, TMD, mineral-to-collagen ratio and intrinsic mechanical properties. In contrast, the low-dose SR did not significantly change all the detection indices of cartilage and bone at both 3 and 6 weeks. CONCLUSION: The high-dose SR treatment can reduce articular cartilage degeneration and subchondral bone remodeling in the rat MMT model of OA.
Authors: Y Henrotin; A Labasse; S X Zheng; P Galais; Y Tsouderos; J M Crielaard; J Y Reginster Journal: J Bone Miner Res Date: 2001-02 Impact factor: 6.741
Authors: H S Gupta; S Schratter; W Tesch; P Roschger; A Berzlanovich; T Schoeberl; K Klaushofer; P Fratzl Journal: J Struct Biol Date: 2005-02 Impact factor: 2.867
Authors: C Sanchez; M A Deberg; N Piccardi; P Msika; J-Y L Reginster; Y E Henrotin Journal: Osteoarthritis Cartilage Date: 2005-09-13 Impact factor: 6.576
Authors: N E Lane; K Brandt; G Hawker; E Peeva; E Schreyer; W Tsuji; M C Hochberg Journal: Osteoarthritis Cartilage Date: 2011-03-23 Impact factor: 6.576
Authors: M A Karsdal; D J Leeming; E B Dam; K Henriksen; P Alexandersen; P Pastoureau; R D Altman; C Christiansen Journal: Osteoarthritis Cartilage Date: 2008-03-24 Impact factor: 6.576
Authors: Timothy K Mwangi; Ian M Berke; Eduardo H Nieves; Richard D Bell; Samuel B Adams; Lori A Setton Journal: J Control Release Date: 2018-05-26 Impact factor: 9.776